Product Description: Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Peipei Liu, et al. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases. Front Immunol. 2020 Nov 27;11:596908./[2]Seung Y Chu, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol. 2012 Apr;129(4):1102-15./[3]Marcia A Chan, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013 Sep 2;3(1):29.
CAS Number: 242138-07-4
Molecular Weight: N/A
Compound Purity: 99.70
Research Area: Inflammation/Immunology; Cancer
Solubility: H2O
Target: Others
English
Deutsch
